Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.

Evidence report/technology assessment (Summary)

Volumn , Issue 4, 1999, Pages

  Seidenfeld, J ^a   Samson, D J ^a   Aronson, N ^a   Albertson, P C ^a   Bayoumi, A M ^a   Bennett, C ^a   Brown, A ^a   Garber, A ^a   Gere, M ^a   Hasselblad, V ^a   Wilt, T ^a   Ziegler, K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN; GOSERELIN; LEUPRORELIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG POTENTIATION; ECONOMICS; EVIDENCE BASED MEDICINE; HUMAN; MALE; ORCHIECTOMY; PATHOLOGY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LEUPROLIDE; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0033122997     PISSN: 1530440X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (330)